Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Haas, M; Mayer, G; Wirnsberger, G; Holzer, H; Ratschek, M; Neyer, U; Neuweiler, J; Kramar, R; Schneider, B; Breiteneder-Geleff, S; Regele, HM; Hörl, WH; Kerjaschki, D.
Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study.
Wien Klin Wochenschr. 2002; 114(4):143-147
Web of Science
PubMed
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Haas Michael
- Co-Autor*innen der Med Uni Graz
- Holzer Herwig
- Ratschek Manfred
- Wirnsberger Gerhard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- BACKGROUND: Proteinuria in Heymann's nephritis, an experimental rat model disease corresponding to membranous nephropathy, has been shown to be due to lipid peroxidation. Since the pathophysiology might be similar to idiopathic membranous nephropathy in humans, we performed a prospective multicenter trial to investigate the efficacy of the lipid peroxidation scavenger, probucol. METHODS: Fifteen patients with biopsy-proven idiopathic membranous nephropathy resistant to conventional immunosuppressive therapy (n = 7) and/or ACEI treatment (n = 12) were recruited. Probucol (1 g/d orally) was administered for three months, followed by a washout period of four weeks, whereon lovastatin (10-20 mg/d orally) was administered for additional three months. RESULTS: A significant reduction in proteinuria was seen during the probucol treatment (median (range): 6.4 (3.8-9.1) g/d vs. 4.7 (1.3-16) g/d; P < 0.05), with partial remission achieved in four patients. Three of these patients had previously been resistant to immunosuppressive therapy. Median protein excretion increased to pretreatment values during the washout period (6.2 (1.9-15) g/d; P < 0.05) and was not significantly different after the intake of lovastatin (4.9 (1.8-19) g/d; P = NS). None of the patients achieved partial remission during lovastatin therapy (P < 0.05 vs. probucol). CONCLUSION: The present study led us to conclude that proteinuria can be reduced by probucol in some patients with idiopathic membranous nephropathy. A randomized multicenter study to further elucidate the influence of lipid peroxidation scavengers on membranous nephropathy is warranted.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Anticholesteremic Agents - therapeutic use
- Antioxidants - adverse effects
- Dose-Response Relationship, Drug - adverse effects
- Drug Administration Schedule - adverse effects
- Female - adverse effects
- Glomerulonephritis, Membranous - drug therapy
- Humans - drug therapy
- Kidney Function Tests - drug therapy
- Lipid Peroxidation - drug effects
- Lovastatin - therapeutic use
- Male - therapeutic use
- Middle Aged - therapeutic use
- Probucol - therapeutic use
- Prospective Studies - therapeutic use
- Proteinuria - drug therapy
- Treatment Outcome - drug therapy
- Find related publications in this database (Keywords)
- membranous nephropathy
- glomerulonephritis
- proteinuria
- antioxidants